Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sildenafil Citrate

FDA-approved product (tablet, oral), marketed as Liqrev, Revatio, Sildenafil Citrate and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sildenafil Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Connective tissue disease
  • Erectile dysfunction
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Impotence
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sildenafil Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sildenafil Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

    NCT02832570 · start 2016-11-07

    Registered record
    Registry ID
    NCT02832570
    Conditions
    Peripheral Arterial Occlusive Disease
    Interventions
    Sildenafil 100mg single oral dose; Placebo, Oral intake single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-11-07
    Completion
    2017-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Arterial Occlusive Disease
    InterventionSildenafil 100mg single oral dose; Placebo, Oral intake single dose
    PhasePhase 3
    Registry statusCompleted

  • Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

    NCT03027674 · start 2016-08

    Registered record
    Registry ID
    NCT03027674
    Conditions
    Raynaud Phenomenon Due to Trauma; Raynaud Disease; System; Sclerosis; Lupus Erythematosus, Systemic; Dermatomyositis; Ultrasound Therapy; Complications
    Interventions
    10% nifedipine cream; 5% sildenafil cream
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2016-08
    Completion
    2016-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRaynaud Phenomenon Due to Trauma; Raynaud Disease; System; Sclerosis +4 more
    Intervention10% nifedipine cream; 5% sildenafil cream
    PhaseEarly phase 1
    Registry statusCompleted

  • The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene

    NCT02663830 · start 2016-01-10

    Registered record
    Registry ID
    NCT02663830
    Conditions
    Anovulatory
    Interventions
    Sildenafil & clomiphene citrate; clomiphene only
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01-10
    Completion
    2017-03-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnovulatory
    InterventionSildenafil & clomiphene citrate; clomiphene only
    PhasePhase 2
    Registry statusCompleted

  • The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

    NCT02546609 · start 2015-11-19

    Registered record
    Registry ID
    NCT02546609
    Conditions
    NAFLD
    Interventions
    Leu-Met-Sil 0.5; Leu-Met-Sil 1.0; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11-19
    Completion
    2017-01-31
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNAFLD
    InterventionLeu-Met-Sil 0.5; Leu-Met-Sil 1.0; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Induction of Migraine Aura With Sildenafil

    NCT02795351 · start 2015-06

    Registered record
    Registry ID
    NCT02795351
    Conditions
    Migraine With Aura
    Interventions
    Sildenafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2021-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura
    InterventionSildenafil; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate

    NCT02337881 · start 2015-01

    Registered record
    Registry ID
    NCT02337881
    Conditions
    Labor Preterm Requiring Hospitalization
    Interventions
    nifedipen; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2016-10
    Enrolment
    227

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLabor Preterm Requiring Hospitalization
    Interventionnifedipen; Sildenafil
    PhasePhase 1
    Registry statusUnknown

  • Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

    NCT01817751 · start 2013-04-11

    Registered record
    Registry ID
    NCT01817751
    Conditions
    Glioblastoma; Recurrent Adult Brain Neoplasm; Malignant Glioma; WHO Grade III Glioma
    Interventions
    sorafenib tosylate; valproic acid; sildenafil citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04-11
    Completion
    2023-05-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Recurrent Adult Brain Neoplasm; Malignant Glioma; WHO Grade III Glioma
    Interventionsorafenib tosylate; valproic acid; sildenafil citrate
    PhasePhase 2
    Registry statusCompleted

  • Revatio Portal-Pulmonary Arterial Hypertension Trial

    NCT01517854 · start 2012-11-14

    Registered record
    Registry ID
    NCT01517854
    Conditions
    Portopulmonary Hypertension
    Interventions
    Sildenafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-11-14
    Completion
    2019-05-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortopulmonary Hypertension
    InterventionSildenafil; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil

    NCT01737203 · start 2012-08

    Registered record
    Registry ID
    NCT01737203
    Conditions
    Healthy
    Interventions
    Viagra; sildenafil ODT; sildenafil ODT
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08
    Completion
    2012-09
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionViagra; sildenafil ODT; sildenafil ODT
    PhasePhase 1
    Registry statusCompleted

  • Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH

    NCT01726049 · start 2011-10

    Registered record
    Registry ID
    NCT01726049
    Conditions
    Heart Failure, Diastolic; Pulmonary Hypertension
    Interventions
    Sildenafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure, Diastolic; Pulmonary Hypertension
    InterventionSildenafil; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Tadalafil and Sildenafil for Duchenne Muscular Dystrophy

    NCT01359670 · start 2011-05

    Registered record
    Registry ID
    NCT01359670
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Tadalafil; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionTadalafil; Sildenafil
    PhaseEarly phase 1
    Registry statusCompleted

  • Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.

    NCT01179334 · start 2010-08

    Registered record
    Registry ID
    NCT01179334
    Conditions
    Pulmonary Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2013-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRiociguat (Adempas, BAY63-2521); Placebo; Sildenafil
    PhasePhase 2
    Registry statusCompleted

  • Sildenafil for Prevention of Cerebral Vasospasm

    NCT01091870 · start 2010-03

    Registered record
    Registry ID
    NCT01091870
    Conditions
    Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm
    Interventions
    Placebo; Sildenafil Citrate, 25 mg, 3 times a day.; Sildenafil Citrate 50 mg, 3 times a day
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2010-03
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm
    InterventionPlacebo; Sildenafil Citrate, 25 mg, 3 times a day.; Sildenafil Citrate 50 mg, 3 times a day
    PhasePhase 2
    Registry statusWithdrawn

  • A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

    NCT00904748 · start 2010-01

    Registered record
    Registry ID
    NCT00904748
    Conditions
    Erectile Dysfunction
    Interventions
    sildenafil citrate 100 mg CT; sildenafil citrate 100 mg CT; Viagra®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-03
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionsildenafil citrate 100 mg CT; sildenafil citrate 100 mg CT; Viagra®
    PhasePhase 1
    Registry statusCompleted

  • Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles

    NCT01668446 · start 2009-09

    Registered record
    Registry ID
    NCT01668446
    Conditions
    Endometrial Preparation; Frozen Embryo Transfer
    Interventions
    Sildenafil; estradiol valerat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-02
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Preparation; Frozen Embryo Transfer
    InterventionSildenafil; estradiol valerat
    PhasePhase 4
    Registry statusCompleted